Floatz logo

Sns-062

Waldenstrom Macroglobulinemia

Sunesis PharmaceuticalsPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

60 Active assets in the Waldenstrom Macroglobulinemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB
Inno-206
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Sns-062 is also rated in:

lymphoplasmacytic lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
mantle cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →